These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8674870)

  • 41. Features of macrovascular complications in type 2 diabetic patients.
    Strojek K
    Acta Diabetol; 2003 Dec; 40 Suppl 2():S334-7. PubMed ID: 14704864
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 15th International Cancer Congress. Proceedings of the satellite symposium on recent advances of Bestatin (ubenimex), Hamburg, August 19, 1990.
    Biomed Pharmacother; 1991; 45(2-3):49-124. PubMed ID: 1680478
    [No Abstract]   [Full Text] [Related]  

  • 43. Fibrinolysis. Proceedings of the Second Osaka Symposium. Osaka, Japan, August 27, 1989.
    Thromb Res Suppl; 1990; 10():1-131. PubMed ID: 2315898
    [No Abstract]   [Full Text] [Related]  

  • 44. A long-term quality-of-care score for predicting the occurrence of macrovascular diseases in patients with type 2 diabetes mellitus.
    Li PI; Wang JN; Guo HR
    Diabetes Res Clin Pract; 2018 May; 139():72-80. PubMed ID: 29481816
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The International Diabetes Federation definition of the metabolic syndrome independently predicts future cardiovascular events in Type 2 diabetic patients. The Valpolicella Heart Diabetes Study.
    Targher G; Bertolini L; Tessari R; Zenari L; Arcaro G
    Diabet Med; 2006 Nov; 23(11):1270-1. PubMed ID: 17054609
    [No Abstract]   [Full Text] [Related]  

  • 46. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey.
    ; Bonadonna R; Cucinotta D; Fedele D; Riccardi G; Tiengo A
    Diabetes Care; 2006 Dec; 29(12):2701-7. PubMed ID: 17130208
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum vaspin concentration in elderly patients with type 2 diabetes mellitus and macrovascular complications.
    Yang W; Li Y; Tian T; Wang L; Lee P; Hua Q
    BMC Endocr Disord; 2017 Oct; 17(1):67. PubMed ID: 29065866
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Carcinogenic and mutagenic effects of diesel engine exhaust. Proceedings of the International Satellite Symposium on Toxicological Effects of Emissions from Diesel Engines. Tsukuba Science City, Japan, July 26-28, 1986.
    Dev Toxicol Environ Sci; 1986; 13():1-539. PubMed ID: 2435482
    [No Abstract]   [Full Text] [Related]  

  • 49. [General concept and pathophysiological mechanisms of progression of macrovascular complications in diabetes].
    Kashiwagi A
    Nihon Rinsho; 2010 May; 68(5):777-87. PubMed ID: 20446569
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Renin inhibitors: present and future. Satellite symposium of the 12th scientific meeting of the International Society of Hypertension. 28 May 1988, Osaka, Japan.
    J Hypertens Suppl; 1989 Apr; 7(2):S1-87. PubMed ID: 2666606
    [No Abstract]   [Full Text] [Related]  

  • 51. Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications.
    Krentz AJ; Clough G; Byrne CD
    Diabetes Obes Metab; 2007 Nov; 9(6):781-91. PubMed ID: 17924862
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proceedings of the International Symposium on Insulin Resistance and Atherosclerosis. Osaka, Japan, 27-29 July 2000.
    J Diabetes Complications; 2002; 16(1):1-132. PubMed ID: 11872357
    [No Abstract]   [Full Text] [Related]  

  • 53. The Worldwide Challenge to Physiome and Systems Biology. Proceedings of the 2nd MEI International Symposium. December 7-9, 2007. Osaka, Japan.
    J Physiol Sci; 2008 Dec; 58(7):425-514. PubMed ID: 19408358
    [No Abstract]   [Full Text] [Related]  

  • 54. The diabetic gangrene: research and clinical practice. Proceedings of a symposium in Umeå, Sweden, October 14-15, 1982.
    Acta Med Scand Suppl; 1984; 687():1-114. PubMed ID: 6591751
    [No Abstract]   [Full Text] [Related]  

  • 55. Cardiovascular Structure and Reactivity in Hypertension. Proceedings of a satellite symposium to the 15th meeting of the International Society of Hypertension. Melbourne, Australia, March 1994.
    Blood Press Suppl; 1995; 2():5-125. PubMed ID: 7582075
    [No Abstract]   [Full Text] [Related]  

  • 56. International Symposium on Diabetes, Vascular Risks, and Gliclazide (Diamicron). Washington, DC, June 28, 1991.
    Metabolism; 1992 May; 41(5 Suppl 1):1-45. PubMed ID: 1349419
    [No Abstract]   [Full Text] [Related]  

  • 57. [Metabolic syndrome].
    Gotoda T
    Nihon Rinsho; 2010 May; 68(5):827-31. PubMed ID: 20446577
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of antihypertensive therapy in reducing vascular complications of type 2 diabetes. Findings from the DIabetic REtinopathy Candesartan Trials-Protect 2 study.
    Tillin T; Orchard T; Malm A; Fuller J; Chaturvedi N
    J Hypertens; 2011 Jul; 29(7):1457-62. PubMed ID: 21602709
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proceedings of the International Ion Chromatography Symposium 1998. Osaka, Japan, 28 September-1 October 1998.
    J Chromatogr A; 1999 Jul; 850(1-2):1-389. PubMed ID: 10532804
    [No Abstract]   [Full Text] [Related]  

  • 60. Orthostatic hypotension in diabetic patients-10-year follow-up study.
    Gaspar L; Kruzliak P; Komornikova A; Celecova Z; Krahulec B; Balaz D; Sabaka P; Caprnda M; Kucera M; Rodrigo L; Uehara Y; Dukat A
    J Diabetes Complications; 2016; 30(1):67-71. PubMed ID: 26412028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.